Corneal Endothelial Dystrophy Market: By Treatment, By Disease Type, By Diagnosis, By End Users and Region Forecast 2020-2031

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Corneal Endothelial Dystrophy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Phototherapeutic Keratectomy, Amniotic Membrane Transplants, Anterior Stromal Puncture, Conjunctival Flaps), By Disease Type (Congenital Hereditary Endothelial Dystrophy 1, Congenital Hereditary Endothelial Dystrophy 2, Posterior Polymorphous Corneal Dystrophy, and Fuchs Endothelial Corneal Dystrophy), By Diagnosis (Cornea Examination and Grading, Corneal Tomography, Corneal Pachymetry, Corneal Cell Count, and Others), By End Users (Hospitals, Clinics, Others) and Region Forecast 2020-2031

checked icon checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Corneal Endothelial Dystrophy Market size was valued at US$ 168 billion in 2023 and is poised to grow at a CAGR of 7.5% over 2024-2030. Corneal endothelial dystrophy is a group of rare hereditary disorders characterized by bilateral abnormal deposition of substances in the cornea. Based on the diagnosis type, the cornea examination and grading segment is anticipated to dominate the market share over the forecast period. According to the American Academy of Ophthalmology, congenital corneal opacities have a prevalence of 6:1,00,000 in newborns and 3:1,00,000 excluding congenital glaucoma patients. With an increasingly aging population, awareness of the disorder is also increasing, driving the corneal endothelial dystrophy market growth. However, the side effects associated with the treatment procedures might hinder the market growth. Initiatives by the government and increasing reimbursement policies are opportunities for the growth of the market.

Key Developments

  • In May 2023, Trefoil Therapeutics released updated efficacy data from the phase-II STORM trial in Fuchs endothelial dystrophy for TTHX-1114.

summary download arrow Download Free Sample

Corneal Endothelial Dystrophy Market Summary

Study Period

2025-2031

Base Year

2024

CAGR

7.5%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific

Corneal Endothelial Dystrophy Market Dynamics

There has been an increase in technologies involved in the diagnosis and treatment of the disease with an increased clinical trial in the eye disease segment owing to the growing healthcare expenditures. For Instance, Rhopressa (Netarsudil ophthalmic solution), developed by Aerie Pharmaceuticals is used in the treatment of Fuchs endothelial corneal dystrophy. Thus, the increased awareness, research, and development for rare disorders will lead to the growth of the market within the forecast period. Whereas the high cost of treatment could pose as a restraining factor for the market growth.

Corneal Endothelial Dystrophy Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2025-2031

Market Size in 2023

US$ 168 billion

Market CAGR

7.5%

By Treatment

  • Phototherapeutic Keratectomy
  • Amniotic Membrane Transplants
  • Anterior Stromal Puncture
  • Conjunctival Flaps

By Disease Type

  • Congenital Hereditary Endothelial Dystrophy 1
  • Congenital Hereditary Endothelial Dystrophy 2
  • Posterior Polymorphous Corneal Dystrophy
  • Fuchs Endothelial Corneal Dystrophy

By Diagnosis

  • Cornea Examination and Grading
  • Corneal Tomography
  • Corneal Pachymetry
  • Corneal Cell Count
  • Others

By End User

  • Hospitals
  • Clinics
  • Others

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The corneal endothelial dystrophy market report provides granular level information about the market size, regional market share, historic market (2019-2023) and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

Corneal endothelial dystrophy narket size was valued at US$ 168 billion in 2023 and is poised to grow at a CAGR of 7.5% from 2024-2030.

Initiatives by the government and increasing reimbursement policies are key opportunities for the market.

An increasing aging population and a rise in awareness of the disorder are the growth drivers in the market.

Kowa Company, Ltd., Trefoil Therapeutics, Alcon, Price Vision Group, ProQR Therapeutics, Emmecell, Pfizer Inc., GlaxoSmithKline plc., Bausch Health Companies Inc., Bayer AG, Allergan, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., and Novartis AG are a few companies operating in the market.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Corneal Endothelial Dystrophy Market Introduction 
2.1.Global Corneal Endothelial Dystrophy Market  - Taxonomy
2.2.Global Corneal Endothelial Dystrophy Market  - Definitions
2.2.1.Treatment
2.2.2.Disease Type
2.2.3.Diagnosis
2.2.4.End User
2.2.5.Region
3.Global Corneal Endothelial Dystrophy Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Corneal Endothelial Dystrophy Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Corneal Endothelial Dystrophy Market  By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Phototherapeutic Keratectomy
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Amniotic Membrane Transplants
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Anterior Stromal Puncture
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Conjunctival Flaps
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Corneal Endothelial Dystrophy Market  By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Congenital Hereditary Endothelial Dystrophy 1
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Congenital Hereditary Endothelial Dystrophy 2
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Posterior Polymorphous Corneal Dystrophy
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Fuchs Endothelial Corneal Dystrophy
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Corneal Endothelial Dystrophy Market  By Diagnosis, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Cornea Examination and Grading
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Corneal Tomography
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Corneal Pachymetry
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Corneal Cell Count
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Others
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8.Global Corneal Endothelial Dystrophy Market  By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Hospitals
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Clinics
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Others
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Corneal Endothelial Dystrophy Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Corneal Endothelial Dystrophy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Phototherapeutic Keratectomy
10.1.2.Amniotic Membrane Transplants
10.1.3.Anterior Stromal Puncture
10.1.4.Conjunctival Flaps
10.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Congenital Hereditary Endothelial Dystrophy 1
10.2.2.Congenital Hereditary Endothelial Dystrophy 2
10.2.3.Posterior Polymorphous Corneal Dystrophy
10.2.4.Fuchs Endothelial Corneal Dystrophy
10.3.  Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Cornea Examination and Grading
10.3.2.Corneal Tomography
10.3.3.Corneal Pachymetry
10.3.4.Corneal Cell Count
10.3.5.Others
10.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospitals
10.4.2.Clinics
10.4.3.Others
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Corneal Endothelial Dystrophy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Phototherapeutic Keratectomy
11.1.2.Amniotic Membrane Transplants
11.1.3.Anterior Stromal Puncture
11.1.4.Conjunctival Flaps
11.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Congenital Hereditary Endothelial Dystrophy 1
11.2.2.Congenital Hereditary Endothelial Dystrophy 2
11.2.3.Posterior Polymorphous Corneal Dystrophy
11.2.4.Fuchs Endothelial Corneal Dystrophy
11.3.  Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Cornea Examination and Grading
11.3.2.Corneal Tomography
11.3.3.Corneal Pachymetry
11.3.4.Corneal Cell Count
11.3.5.Others
11.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospitals
11.4.2.Clinics
11.4.3.Others
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Corneal Endothelial Dystrophy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Phototherapeutic Keratectomy
12.1.2.Amniotic Membrane Transplants
12.1.3.Anterior Stromal Puncture
12.1.4.Conjunctival Flaps
12.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Congenital Hereditary Endothelial Dystrophy 1
12.2.2.Congenital Hereditary Endothelial Dystrophy 2
12.2.3.Posterior Polymorphous Corneal Dystrophy
12.2.4.Fuchs Endothelial Corneal Dystrophy
12.3.  Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Cornea Examination and Grading
12.3.2.Corneal Tomography
12.3.3.Corneal Pachymetry
12.3.4.Corneal Cell Count
12.3.5.Others
12.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospitals
12.4.2.Clinics
12.4.3.Others
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Corneal Endothelial Dystrophy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Phototherapeutic Keratectomy
13.1.2.Amniotic Membrane Transplants
13.1.3.Anterior Stromal Puncture
13.1.4.Conjunctival Flaps
13.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Congenital Hereditary Endothelial Dystrophy 1
13.2.2.Congenital Hereditary Endothelial Dystrophy 2
13.2.3.Posterior Polymorphous Corneal Dystrophy
13.2.4.Fuchs Endothelial Corneal Dystrophy
13.3.  Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Cornea Examination and Grading
13.3.2.Corneal Tomography
13.3.3.Corneal Pachymetry
13.3.4.Corneal Cell Count
13.3.5.Others
13.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospitals
13.4.2.Clinics
13.4.3.Others
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Corneal Endothelial Dystrophy Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Phototherapeutic Keratectomy
14.1.2.Amniotic Membrane Transplants
14.1.3.Anterior Stromal Puncture
14.1.4.Conjunctival Flaps
14.2.  Disease Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Congenital Hereditary Endothelial Dystrophy 1
14.2.2.Congenital Hereditary Endothelial Dystrophy 2
14.2.3.Posterior Polymorphous Corneal Dystrophy
14.2.4.Fuchs Endothelial Corneal Dystrophy
14.3.  Diagnosis Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Cornea Examination and Grading
14.3.2.Corneal Tomography
14.3.3.Corneal Pachymetry
14.3.4.Corneal Cell Count
14.3.5.Others
14.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospitals
14.4.2.Clinics
14.4.3.Others
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Kowa Company, Ltd.
15.2.2.Trefoil Therapeutics
15.2.3.Alcon
15.2.4.Price Vision Group
15.2.5.ProQR Therapeutics
15.2.6.Emmecell
15.2.7.Pfizer Inc.
15.2.8.GlaxoSmithKline plc.
15.2.9.Bausch Health Companies Inc.
15.2.10.Bayer AG
15.2.11.Allergan
15.2.12.Teva Pharmaceutical Industries Ltd.
15.2.13.Merck & Co., Inc.
15.2.14.Novartis AG
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  • Kowa Company, Ltd.
  • Trefoil Therapeutics
  • Alcon
  • Price Vision Group
  • ProQR Therapeutics
  • Emmecell
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Allergan
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • Novartis AG

Related Industry Reports

Research Use Only Market

Intraoperative Radiation Therapy Market

Extracorporeal Membrane Oxygenation Machine Market

Chronic Refractory Gout Pharmaceuticals Market